Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bide Pharmatech CoSHSE:688073 +1.45%88 Debt-to-EBITDA is 0.45 as of Jun. 2026, which is 10% above its 10-year median of 0.41. GuruFocus rates SHSE:688073 with a GF Score™ of 88/100 and a GF Value™ of ¥64.49 (Fairly Valued). The stock has 3 warning signs investors should review. Among 676 Drug Manufacturers companies, Bide Pharmatech Co ranks better than 69.23% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Bide Pharmatech Co's Debt-to-EBITDA or its related term are showing as below:
SHSE:688073'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.57 Med: 0.41 Max: 2.09
Current: 0.58
During the past 8 years, the highest Debt-to-EBITDA Ratio of Bide Pharmatech Co was 2.09. The lowest was -2.57. And the median was 0.41.
SHSE:688073's Debt-to-EBITDA is ranked better than 69.23% of 676
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs SHSE:688073: 0.58
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Bide Pharmatech Co Debt-to-EBITDA Related Terms
Bide Pharmatech Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Bide Pharmatech Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bide Pharmatech Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bide Pharmatech Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bide Pharmatech Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bide Pharmatech Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Bide Pharmatech Co (SHSE:688073) has a Debt-to-EBITDA of 0.45 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bide Pharmatech Co. This is 10% above median its historical median of 0.41. According to the industry distribution chart, Bide Pharmatech Co ranks #208 out of 676 companies in the Drug Manufacturers industry, placing it in the top 30.8%.
Is Bide Pharmatech Co's Debt-to-EBITDA too high?
Bide Pharmatech Co's current Debt-to-EBITDA of 0.45 is 10% above median its 10-year median of 0.41. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Bide Pharmatech Co's value of 0.45 is 72.6% below this industry median. Based on the distribution chart, Bide Pharmatech Co ranks #208 out of 676 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bide Pharmatech Co has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bide Pharmatech Co's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bide Pharmatech Co ranks #208 out of 676 companies for Debt-to-EBITDA. This puts Bide Pharmatech Co in the upper half of its industry. The industry median Debt-to-EBITDA is 1.64. Bide Pharmatech Co's value of 0.45 is 72.6% below this benchmark. While the company's 10-year median is 0.41 vs. the industry median of 1.64, Bide Pharmatech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 676 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bide Pharmatech Co's current Debt-to-EBITDA of 0.45 is 72.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bide Pharmatech Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bide Pharmatech Co's current Debt-to-EBITDA is 0.45, which is 10% above median its own 10-year median of 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bide Pharmatech Co stock overvalued right now?
Based on GuruFocus' analysis, Bide Pharmatech Co (SHSE:688073) is currently considered Fairly Valued. The stock's GF Value™ is ¥64.49, compared to a current price of ¥59.44 — trading 7.8% below its estimated fair value. The current Debt-to-EBITDA is 0.45, which is 10% above median its 10-year median of 0.41 and 72.6% below the Drug Manufacturers industry median of 1.64. Bide Pharmatech Co's overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Bide Pharmatech Co (SHSE:688073), the current Debt-to-EBITDA is 0.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bide Pharmatech Co (SHSE:688073) Overvalued in 2026?
Based on GuruFocus' analysis, Bide Pharmatech Co stock appears to be undervalued.
The current stock price of ¥59.44 is trading 7.8% below its estimated GF Value™ of ¥64.49.
GuruFocus considers Bide Pharmatech Co to be Fairly Valued.
Key valuation signals for SHSE:688073:
Debt-to-EBITDA: 0.45 (10% above median its 10-year median of 0.41)
GF Value™: ¥64.49 vs. price of ¥59.44 (7.8% below fair value)
Industry Position: 72.6% below the Drug Manufacturers median (#208 of 676)
No single metric tells the full story. See the SHSE:688073 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688073 has been successfully added to your 
